|
|
||||||||

*
Department of Pathology and Laboratory Medicine and Jonsson Comprehensive Cancer Center, University of California School of Medicine, Los Angeles, CA 90095; and
Division of Rheumatology, Allergy, and Clinical Immunology, University of California School of Medicine, Davis, CA 95616
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
This conclusion is based on the finding that NZB bone marrow cells are less efficient at differentiating into mature T cells in fetal thymic organ cultures (FTOCs) compared with cells from control mice. However, the mechanism(s) responsible for this deficiency was not defined. Doing so is critically important, because such information would provide insights into how T lineage differentiation is regulated and could potentially provide a basis for understanding how defects in that process contribute to development of the autoimmune phenotype.
One possibility is that T cell precursors in the bone marrow of NZB mice are deficient in their ability to migrate to the thymus in response to chemotactic signals produced by that organ (13, 14). Upon reaching the thymus, cells have to enter the thymic parenchyma (15) and this process, which involves the interaction between cell surface receptor expressed on the precursors with ligands presented by the vascular endothelium and thymic stroma, might also be impaired in NZB mice. In either case, fewer T cell precursors would enter the thymus, and this in turn could be manifested as a reduction in the number of T lineage cells that are produced.
Additional defects in NZB T cell precursors must also be considered. For example, previous results from this laboratory demonstrated that the diminished thymus repopulating potential of NZB bone marrow cells was an intrinsic defect that could be localized to the pluripotent hematopoietic stem cell (PHSC) compartment (12). However, PHSCs are difficult to detect in the thymus and they may not be the cell population that normally migrates to that organ and sustains thymopoiesis. Instead, more differentiated PHSC progeny, such as the common lymphoid precursor (CLP) (16) or a T cell-committed prothymocyte (17, 18, 19) may be the bone marrow emigrant population. If development of these progeny from the PHSCs is defective, NZB bone marrow would contain fewer T cell precursors, thus explaining their deficiency in thymus repopulation. Alternatively, CLPs and prothymocytes may develop in normal numbers, but their ability to respond to developmental signals upon entry into the thymic microenvironment could be impaired.
The aim of this study is to distinguish between these possibilities to define a basis for the decreased thymus repopulating potential of NZB bone marrow. The data indicate that the reduced capacity of NZB bone marrow cells to repopulate the thymus does not result from their inability to migrate to or enter the thymus. Instead, the results suggest that their T lymphopoietic defect results from an impaired ability of PHSCs to generate CLPs and/or T cell-committed progenitors. Taken together, the results identify an unappreciated defect in NZB mice and provide further evidence that the generation of lymphoid progeny from the PHSCs is a regulated event.
| Materials and Methods |
|---|
|
|
|---|
C57BL/6J (H-2b; Thy 1.2), NZB/BNJI (H-2d; Thy-1.2), and BALB/c By (H-2d;Thy-1.2) mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and were housed in the Division of Laboratory Animal Medicine vivarium at the University of California (Los Angeles, CA). Timed pregnant Swiss/Webster (S/W; H-2s/q;Thy 1.1) mice were purchased from Taconic Farms (Germantown, NY).
Preparation of cell suspensions
Bone marrow cell suspensions were prepared by flushing femurs and tibiae with 3 ml of RPMI 1640. Thymocyte suspensions were prepared by gently pressing thymuses through a fine mesh screen into RPMI 1640. Cells were counted with a hematocytometer, and cell viability, determined by eosin dye exclusion, was always >95%.
FTOCs
FTOCs were initiated and maintained based on the protocol established by Jenkinson et al. (20), as described previously (12). Briefly, embryonic thymuses were aseptically harvested from timed pregnant S/W mice at day 14 of gestation. The thymus lobes were dissected free from extraneous tissue and cultured for 5 days in the presence of 1.35 mM deoxyguanosine (dGuo; Sigma-Aldrich, St. Louis, MO) to deplete endogenous lymphohematopoietic cells. The lobes were then rinsed and incubated in hanging drop cultures in Terasaki plates (Nunc; Fisher, Pittsburgh, PA) for 48 h with bone marrow cells enriched in lineage-negative population of bone marrow (Lin-) or CLPs. Subsequently, lobes were transferred to FTOCs on filter/gelfoam rafts in RPMI 1640 supplemented with 10% FCS, 5 x 10-5 2-ME, 100 U/ml streptomycin, and 100 U/ml penicillin and placed in a humidified incubator (37°C, 5% CO2, and air). After 1421 days of culture, thymocytes were harvested by gently pressing the lobes through fine mesh sieves with the plunger of a sterile 1-ml syringe. Donor cell origin was always confirmed on the basis of Thy-1-allotypic differences.
Thymus reaggregate cultures
Thymus reaggregate organ cultures were established based on the protocol described by Anderson et al. (21). Deoxyguanosine-treated S/W fetal lobes were digested in collagenase dispase (Sigma-Aldrich) in Ca2+, Mg2+-free PBS for 30 min at 37°C. The reaction was stopped by the addition of Ca2+, Mg2+-free PBS, and the suspension was vigorously pipetted and dispersed with a syringe fitted with a 21-gauge needle. To make reaggregates, sorted Lin- bone marrow cells were mixed with dispersed stromal cells at a ratio of 1:10. After centrifugation, the cell slurry was placed on the surface of a millipore filter in organ culture. After 3 wk of culture, the reaggregates were processed as described above for FTOCs.
Migration assay
Deoxyguanosine-treated fetal thymic lobes were placed in wells of six-well plates in RPMI 1640 supplemented with 10% FCS, 5 x 10-5 2-ME, 100 U/ml streptomycin, and 100 U/ml penicillin. Transwells with 0.4-µm pore membranes, into which smaller transwells with 5-µm pore membranes were inserted, were placed over each well. A total of 106 bone marrow cells were then deposited into the 5-µm wells. Following a 24-h incubation at 37°C, the number of cells trapped in the 0.4-µm chamber was determined on a FACScan (BD Biosciences, San Jose, CA) calibrated for automatic cell counting. Incubation of 106 cells in the absence of fetal thymic lobes in this experimental system was used to determine random migration through the 5-µm membranes. A chemotactic index was then calculated by dividing the number of cells that migrated toward wells that included thymic lobes by the number of cells that migrated randomly.
Hematopoietic cell isolation
Bone marrow cell suspensions were depleted of mature lineage cells (Lin-) (22, 23) by magnetic depletion according to the manufacturers instructions (Miltenyi Biotec, Auburn, CA). Briefly, cell suspensions were incubated with the appropriate concentrations of rat anti-lineage Ags CD45R/B220 (clone RA3-6B2), TER-119, Gr-1 (clone RB6-8C5), CD8 (clone 53-6.7), CD2 (clone RM2-5), and CD11b (clone M1/70) (all from BD PharMingen, San Diego, CA) at 4°C in Ca2+, Mg2+-free PBS. Cells were then washed and incubated with goat anti-rat IgG Abs conjugated to MACS microbeads (Miltenyi Biotec) before application to a preconditioned MACS separation column. The Lin--enriched fraction was then incubated with an anti-rat Ig Ab conjugated with Tricolor to exclude remaining mature cells during the sorting procedure.
After blocking of residual anti-rat Ig activity by incubation with unlabeled rat IgG, Lin--enriched cells were labeled with appropriate Abs to enrich for PHSCs (Lin-Sca-1+ (clone E13-161.7), CD117+ (clone 2B8)) and CLPs (CD127+Sca-1lowCD117low). All Abs were obtained from BD PharMingen. Cells with these phenotypes were isolated by flow cytometry on a dual-laser BD Biosciences FACSVantage flow cytometer located in the Jonsson Comprehensive Cancer Center (Los Angeles, CA).
CD4-CD8- thymocytes were isolated by magnetic depletion after incubation with anti-CD4 (clone GK1.5)- and anti-CD8 (clone 53-6.7)-conjugated MACS microbeads, according to the manufacturers instructions. FACS analysis demonstrated that an enrichment of >95% could be routinely achieved by this procedure.
Immunofluorescence
Cells were analyzed for the expression of the following cell
surface determinants: Thy-1.2, CD44, CD25, CD4, and CD8, using Abs
conjugated to fluorescein, PE, or biotin (all from BD PharMingen).
Biotinylated Abs were revealed with PerCP-streptavidin (BD
Biosciences). The optimal working dilution was determined for each
reagent before use. Before staining, Fc
II/IIIR on cells were blocked
by preincubation of the samples with a rat anti-CDw32/16 Ab (BD
PharMingen). Cells were then incubated with the first-step Ab for 30
min at 4°C, washed with Ca2+,
Mg2+-free PBS, and incubated an additional 30 min
at 4°C with the second-step reagent. After the last wash, the cells
were resuspended in Ca2+,
Mg2+-free PBS, and 103
viable cells from each sample were analyzed on a FACScan (BD
Biosciences).
Statistics
The Student t test was used to determine the significance of FTOC data.
| Results |
|---|
|
|
|---|
Previous observations demonstrated that bone marrow cells from NZB
mice are deficient in their ability to repopulate fetal thymic lobes
(12). As shown in Fig. 1
A, although 96% of cells
recovered from FTOCs seeded with Lin- NZB bone
marrow cells were donor derived, a consistent finding was that total
cellularity was lower than in lobes seeded with cells from control
mice. Further analysis demonstrated that the frequency of cells that
had matured to the CD4+CD8+
stage of development was also lower in lobes colonized with NZB
compared with control bone marrow cells (Fig. 1
B). In the
experiment shown, the frequency of CD8+ cells is
higher in lobes repopulated with NZB donor cells, but this is not a
consistent finding (12). The lower cell number in thymic
lobes repopulated with NZB bone marrow cells is in agreement with
histological analysis showing that thymuses seeded with NZB donor cells
are relatively hypocellular (Fig. 1
C).
|
NZB bone marrow cells can migrate to the thymus
The possibility that NZB bone marrow cells were defective in their
ability to migrate to the thymus was examined using a diffusion chamber
culture system depicted in Fig. 2
A. Bone marrow cells from NZB
and BALB/c mice were placed in a diffusion chamber that separated them
from deoxyguanosine-treated thymic lobes present in a lower chamber.
Twenty-four hours later, cells that accumulated in an intermediate
chamber were harvested and counted. As shown in Fig. 2
B, no
significant difference in the ability of unseparated NZB and BALB/c
bone marrow cells to migrate toward the thymic lobes was detected.
Whole bone marrow is heterogeneous, and multiple cell types could have
migrated toward the thymus, regardless of whether or not they had T
lymphoid potential. Therefore, an additional experiment was conducted
to measure the ability of Lin-, CD127
(IL-7R
)-expressing cells to migrate toward the thymus.
Lin-CD127+ cells were
isolated from NZB or control bone marrow, and equivalent numbers were
assayed as shown in Fig. 2
A. The data in Fig. 2
B
indicate that lymphoid-enriched precursors from NZB mice migrate
normally to the thymus.
|
Taken together, these results suggest that the thymopoietic defects of
NZB bone marrow cells should be apparent, even when the need to migrate
to and enter the thymus is obviated. This was confirmed in a thymic
reaggregate system that allows direct interactions between T
cell precursors and thymic stroma (21). Thymic reaggregate
cultures were initiated with NZB or BALB/c Lin-
bone marrow cells, and thymocyte development was analyzed 3 wk later.
As shown in Fig. 3
, >90% of the
thymocytes that developed in the reaggregated lobes were donor-derived
cells as determined by expression of the donor Thy-1.2 allele. The data
further demonstrate that thymocyte numbers and the frequency of
CD4+CD8+,
CD4+, and CD8+ cells were
lower in lobes repopulated with Lin- bone marrow
cells from NZB mice.
|
In view of the above findings, subsequent experiments focused on
the development of lymphoid progeny from PHSCs and their immediate
progeny, such as the CLP. The CLP is one of the earliest PHSC-derived
populations with T lymhopoietic potential (16). Fig. 4
A presents the sorting
strategy used to identify and isolate PHSCs and CLPs. The PHSC
purification strategy was described previously (12), and
enrichment of CLPs was based on the
Lin-CD127+CD117+Sca-1+
phenotype described by Kondo et al. (16). An aliquot of
sorted CLP was used to confirm that cells so identified lacked
myelopoietic potential (data not shown). Fig. 4
B presents
data showing the isolation of CLPs from NZB and control strains, which
were used to initiate FTOC.
|
|
Taken together, the above data suggest that defects in the ability
of NZB CLP to generate thymocytes are minimal to nonexistent. A
prediction based on this conclusion is that differentiated, downstream
progeny of NZB CLPs would also exhibit normal T lymphopoietic
potential. To test this hypothesis,
CD4-CD8- thymocytes, from
NZB and BALB/c mice, which include the earliest intrathymic T cell
progenitor population, were isolated and used to seed FTOCs. As shown
in Table I
, no significant
difference in cellularity between lobes seeded with the two donor
populations was observed. These results are consistent with data
indicating that CD4-CD8-
cells from NZB and BALB/c mice proliferate to similar levels in
response to IL-7 (data not shown). The data in Table I
also show no
differences in the generation of
CD4+CD8+-expressing cells
from NZB and BALB/c mice.
|
| Discussion |
|---|
|
|
|---|
One possibility that was considered to explain these data is that NZB
PHSCs are defective in their ability to generate normal numbers of
CLPs. In this case, fewer progenitors capable of rapid T cell
generation in FTOC would be present in the bone marrow. A reanalysis of
our previous data in which FTOCs were repopulated with PHSCs from NZB
and control strains (12) supports this premise. For
example, the number of thymocytes in FTOCs repopulated with 50 PHSCs
from NZB mice was
3-fold lower than in lobes seeded with 50 PHSCs
from BALB/c mice. If the PHSC defect is simply due to their inability
to generate normal numbers of CLPs and/or prothymocytes, increasing
numbers of PHSCs should compensate for this defect and mediate thymus
repopulation comparable to that in control mice. In this regard, thymic
cellularity in FTOCs repopulated with 500 NZB PHSCs was comparable to
that in lobes seeded with 50 PHSCs from BALB/c or C57BL/6 mice
(12).
Attempts were made to determine whether the frequency of CLPs was
reduced in the bone marrow of NZB vs control strains of mice. However,
performing accurate quantitative analysis on such populations between
different mice is extremely difficult. One reason for this is that
there are subtle strain differences in the expression of cell surface
determinants used in the identification of rare hematopoietic precursor
populations. This likely explains why, although the CLP frequency in
NZB mice was lower than in the C57BL/6 strain (Fig. 4
), no difference
was observed upon comparison to BALB/c mice (data not shown).
Compounding these problems is the fact that there is no ideal control
strain to which NZB mice can be compared (12).
As observed previously (12), PHSCs from NZB mice exhibited
a defect in their capacity to generate
CD4+CD8+ thymocytes in
FTOC. However, when CLP-enriched cells from NZB mice were used, the
defect in the generation of CD4+ and
CD8+ thymocytes was not as severe. This finding
supports the hypothesis that the primary developmental block in NZB
mice occurs at the PHSC to CLP stage. However, further abnormalities in
the ability of NZB CLPs to differentiate cannot be formally excluded
because the frequency of CD4-expressing cells remained below that
observed in lobes repopulated with CLPs from C57BL/6 mice (Fig. 5
B). Once again, these differences may be due to strain
effects and not developmental defects in NZB CLPs. The fact that the
frequencies of thymocyte subpopulations expressing CD44 and/or CD25
were comparable in lobes seeded with NZB and C57BL/6 CLPs (data not
shown) and that the thymus-repopulating potentials of intrathymic
progenitors from NZB and BALB/c mice were similar would support this
latter conclusion.
Although the T lineage defects described herein were observed in NZB mice 3 mo of age and older, deficiencies in the total number and frequency of T cell subpopulations in the thymus of NZB mice in vivo are not observed. One reason for this is that the FTOC system may reveal defects that are not apparent in vivo. In vitro, only one wave of T cell development can occur from a finite number of T cell precursors present in the seed inoculum. However, in vivo there is a continuous input of bone marrow T cell precursors to the thymus (13, 14). Thus, over time enough progenitors might migrate to the thymus and fill all available microenvironmental niches (15). However, a prediction based on the findings herein is that the NZB T lineage generative defect might be exhibited in instances when rapid T cell generation is required. For example, after bone marrow transplantation, a detailed kinetic analysis with limiting numbers of NZB bone marrow cells might reveal a slower rate of thymic repopulation.
Proposing the existence of abnormalities in NZB PHSCs is not unprecedented (1, 26, 27), although the definition of their defect in generating lymphoid committed progeny heretofore has not been appreciated. Interestingly, Sudo et al. (28) recently reported that the ability of PHSCs from aging mice to generate lymphoid progeny is impaired. Those authors noted that mice that received a transplant of bone marrow cells from aged donors exhibited myeloid, but not lymphoid, reconstitution. Thus, the T lineage defect that occurs in NZB mice may be similar to what occurs during aging. Nevertheless, a clear definition of why lymphoid developmental defects occur in NZB mice remains elusive, because the events that regulate the commitment of PHSCs to the CLP and the subsequent decision of the latter cells to generate B- or T-committed progeny are incompletely understood. Based on the present findings, the NZB mouse may provide an appropriate model system by which such regulatory pathways can be studied.
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Kenneth Dorshkind, Department of Pathology and Laboratory Medicine, University of California School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095-1732. E-mail address: kDorshki{at}mednet.ucla.edu ![]()
3 Abbreviations used in this paper: NZB, New Zealand Black; FTOC, fetal thymic organ culture; PHSC, pluripotent hematopoietic stem cell; CLP, common lymphoid precursor; S/W, Swiss/Webster; Lin-, lineage-negative population of bone marrow. ![]()
Received for publication August 28, 2001. Accepted for publication October 22, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. L. Fletcher, N. Seach, J. J. Reiseger, T. E. Lowen, M. V. Hammett, H. S. Scott, and R. L. Boyd Reduced Thymic Aire Expression and Abnormal NF-{kappa}B2 Signaling in a Model of Systemic Autoimmunity J. Immunol., March 1, 2009; 182(5): 2690 - 2699. [Abstract] [Full Text] [PDF] |
||||
![]() |
N.-H. Chang, R. MacLeod, and J. E. Wither Autoreactive B Cells in Lupus-Prone New Zealand Black Mice Exhibit Aberrant Survival and Proliferation in the Presence of Self-Antigen In Vivo J. Immunol., February 1, 2004; 172(3): 1553 - 1560. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hashimoto, E. Montecino-Rodriguez, H. Leathers, R. P. Stephan, and K. Dorshkind B-cell development in the thymus is limited by inhibitory signals from the thymic microenvironment Blood, November 15, 2002; 100(10): 3504 - 3511. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |